Flerie Ab · OMXSTO:FLERIE
Flerie Ab — Q3 2024 Earnings Presentation
18 slides from Flerie Ab's earnings presentation, Oct 16, 2024
Slide 1: Advancing life science innovations – Q3 2024 report presentation
Advancing life science innovations – backed up with a share redemption scheme Q3 2024 – report presentation 16th October 2024 Ted Fjällman, CEO Cecilia Schéele, CFO
Slide 2: Disclaimer
Disclaimer IMPORTANT: You must read the following before continuing. The following applies to this document, the oral presentation of the information in this document by Flerie AB publ (the “Company”) or any person on behal f of the Company, and any question-and-answ er session that follows the oral
Slide 3: Flerie in brief: Our way of working and proven track record
FLERIE IN BRIEF Our way of working and proven track record set us apart Active board engagement Product roadmaps and platform expansion Peer-to-peer network Public Private 14% IRR per year Collaborations and (2011-2023) synergies to advance An active investment company with a diversified portfolio o
Slide 4: An active portfolio approach delivers results
Q3 An active portfolio approach delivers results Syndication and development progress in Q3 2024
Slide 5: Net asset value and fire power
FLERIE Q3 2024 Net asset value and fire power SEK 4,262 m SEK 911,3 m NET ASSET VALUE CASH & EQUIVALENTS 54.59 SEK/share 11.67 SEK/share (out of 54.59 SEK/share) Top tier European investment To be invested to create further company with significant assets value in the current portfolio As of 30 Sept
Slide 6: Flerie catalyses significant investments
FLERIE Q3 2024 Flerie catalyses significant investments SEK 30 million SEK 12 million SEK 40 million (Flerie: SEK 21.5 million) (Flerie: SEK 3 million) (Flerie: SEK 10 million) Syndicating partners invested SEK 47.5 million alongside Flerie’s SEK 34.5 million 6
Slide 7: Significant value changes during the quarter
FLERIE Q3 2024 Significant value changes during the quarter SEK +66 million SEK +60 million SEK -173 million 7
Slide 8: Portfolio company deep-dive: Lipum
PORTFOLIO COMPANY DEEP-DIVE Product development segment KEY EVENTS DURING THE QUARTER ABOUT LIPUM’S LEAD CANDIDATE SOL-116 → Dr. Peter Hovstadius appointed Chief Medical Officer • A humanised antibody in clinical stage supported by solid data for rheumatoid → Last patient enrolled in the phase 1 stu
Slide 9: Portfolio company deep-dive: Xintela
PORTFOLIO COMPANY DEEP-DIVE Product development segment KEY EVENTS DURING THE QUARTER ABOUT XINTELA → Extension of clinical study with XSTEM in knee • Allogeneic stem cell-based treatments osteoarthritis patients focusing on osteoarthritis and difficult-to-treat leg ulcers. → Agreement with Region Ö
Slide 10: Portfolio company deep-dive: Xspray Pharma
PORTFOLIO COMPANY DEEP-DIVE Product development segment KEY EVENTS DURING THE QUARTER ABOUT XSPRAY PHARMA → XS003 study shows matching bioavailability to Tasigna • Unique technology to improve life quality and at more than a 50% lower dose enhance access to improved Protein Kinase Inhibitor drugs fo
Slide 11: Key developments in the private portfolio
FLERIE Q3 2024 Key developments in the private portfolio Regulatory approvals in the Completion of first part of EU and UK to initiate phase Positive FDA feedback on phase 1b/2a trial of ACO1 – a 1b studies in melanoma and the development strategy potential groundbreaking ulcerative colitis patients
Slide 12: Q3 2024 in numbers
Q3 2024 in numbers Cecilia Schéele, CFO
Slide 13: Financial information in summary
PERFORMANCE IN Q3 2024 Financial information in summary July - September January - September Full year 2024 2023 2024 2023 2023 Net asset value (SEK million) 4,262 3,212 4,262 3,212 3,566 Net asset value per share (SEK) 54.59 52.88 54.59 52.88 58.71 Net asset value per share, adjusted (SEK) 55.91 52
Slide 14: Financial highlights per segment
PERFORMANCE IN Q3 2024 Financial highlights per segment Product Development Commercial Growth Limited Partnerships • Fair value: 2,354 (2,222) • Fair value: 547 (652) • Fair value: 92 (64) • Change in FV: -41 (-266) • Change in FV: -80 (-38) • Change in FV: -0 (2) • Investments: 30 • Investments: 10
Slide 15: Redemption scheme provides annual liquidity option
PERFORMANCE IN Q3 2024 Redemption scheme provides annual liquidity option 30% 5% of all shares can be redeemed SEK SEK once a year at 42.09 54.59 NAV/share* Share price NAV/share Sept 30, 2024 Sept 30, 2024 * For more information, please visit www.flerie.com 15
Slide 16: Concluding remarks
Concluding remarks Ted Fjällman, CEO
Slide 17: Advancing innovations across stages
CONCLUDING REMARKS Advancing innovations across stages Preclinical Phase 1 Phase 2 Phase 3 / Pivotal stage Early commercialisation Commercial growth Development stage Frontier Biosolutions # of companies 7 6 6 2 4 4 FV (SEKm) 293 921 809 331 323 294 % of Total FV 10% 31% 27% 11% 11% 10% PRODUCT DEVE
Slide 18: Questions & Answers
Questions & Answers Ted Fjällman, CEO Cecilia Schéele, CFO